Figure 7.

Inhibition of PI3Kinase prevents troglitazone-induced decreases in c-Myc protein. (A) C4-2 cells were treated with DMSO vehicle or troglitazone 45 εM in the presence or absence of MG132 (proteasome inhibitor), LY294002 (PI3Kinase inhibitor) or SB216763 (GSK3β inhibitor) for 24 h. Following treatment, protein gel blot analysis was used to measure the levels of c-Myc and actin protein in treated cells. (B) Cells were treated for 24 h with DMSO vehicle or troglitazone 45 εM in the presence or absence of LY294002 (20–40 εM). Protein gel blot analysis was used to measure levels of c-Myc, p-Akt and Akt in each sample. (C) C4-2 cells were treated for 24 h with DMSO vehicle or troglitazone 45 εM in the presence or absence of SP600125 (10–20 εM) (JNK inhibitor). Protein gel blot analysis was used to measure levels of c-Myc, p-JNK, JNK and actin in treated cells.